Drugs / EBV-specific TCR-T cell with cytokine auto-secreting element
EBV-specific TCR-T cell with cytokine auto-secreting element
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04509726 | Mar 2023 → Jan 2026 | nasopharyngeal carcinoma | Xinqiao Hospital of Chongqing | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBV-specific TCR-T cell with cytokine auto-secreting element | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04509726 ↗ |
| Modality | Cell therapy | “Engineered T cells bearing a TCR (TCR-T)” NCT04509726 ↗ |